Various groups have demonstrated that mutated BRaf or NRas accompanied by ablation of coding sequences or loss of function mutations in either PTEN or p16/INK4 will stimulate senescent cells to re-enter the cell cycle and progress to melanoma in vivo [27, 40, 41]. This evidence concerns the gene CDKN2A and melanoma.